Adults who received the flu vaccine in 2017 to 2018 had higher antibody titers against the egg-adapted vaccine and lower titers against circulating virus.
Influenza vaccine efficacy, between November 23, 2018 and February 2, 2019, was 47% overall and 61% for young children.
The FDA has accepted for review the sNDA for for Xofluza for the treatment of influenza in patients at high risk of complications.
Oseltamivir should be administered to treat critically ill individuals with influenza, particularly when A/H3N2 is circulating.
In otherwise healthy patients, influenza treatment with baloxavir marboxil was found to be comparable, and on some efficacy measures, superior to neuraminidase inhibitors.
Rapid molecular tests for viral pathogen detection provide accurate results and implementation in hospital settings is recommended.
Tafenoquine has performed comparably with primaquine in terms of hemoglobin level decrease in individuals with malaria and normal glucose-6-phosphate dehydrogenase enzyme levels.
The approval was based on findings from a Phase 4 safety and immunogenicity study that included ~2000 children.